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The import into peroxisomes and maturation of peroxisomal 3.oxoacyl-CoA thiolase are impaired in patients with the Rhizomelic form of 
Chondrodysplasia Punctata (RCDP). Were we show by means ofimmunoblouine a dsubcellular fractionation thnt non-specific lipid transfer 
protein (nsLTP), another peroxisomal pm&l synthesiscd as a larger precursor, is localised in peroxisomes and is present as the mature protein 
in RCDP Bbroblasts. Thus the component of the import machinery defective in RCDP is not required for the import or nsLTP into peroxisomes. 
Peroxisome; Rhizomelic Chondrodysplasia Punctata; Non-specilic lipid transfer protein; Sterol carrier protein 2; Puroxisomal 3-oxoacyl-CoA 
thiolase 
1. INTRODUCTION 
Peroxisomes, which are subcellular organelles first 
characterised biochemically in the 1960’s by De Duvc 
and co-workers [l], contain enzymes involved in a 
number of important metabolic processes uch as the 
@-oxidation of very-long-chain fatty acids and the bio- 
synthesis of ether phospholipids (reviewed in [2]). In 
recent years various inherited iseases in man have been 
described in which one or several peroxisomal functions 
are impaired [3-81. In one category of such diseases, 
exemplified by the cerebra-hepato-renal (Zellweger) 
syndrome (ZS), morphologically distinguishable pero- 
xisomes are decreased in number or even absent and 
there is a generalised loss of peroxisomal functions [3- 
61. The genetic defect in such disorders is thought to 
involve the import system for a variety of peroxisomal 
proteins [6]. In a second category of peroxisomal dis- 
eases there is a deficiency of a single peroxisomal en- 
zyme, presumably due to a mutation in the structural 
gene for that enzyme. 
A third category of peroxisomal diseases comprises 
the Rhizomelic form of Chondrodysplssia Punctata 
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(RCDP). This disease is character&d by an impairment 
in ether phospholipid biosynthesis [g-12], a decreased 
capacity to catabolise phytanic acid [g-12], and a defect 
in the import into peroxisomes and subsequent matura- 
tion of peroxisomal 3-oxoacyl-CoA thiolase [13-161. In 
contrast o most peroxisomal proteins, 3-oxoacyl-CoA 
thiolase is synthesised as a larger precursor [17,18] that 
is cleaved after association of the enzyme with pero- 
xisomes [191. The C-terminal tripcptide sequence, -(Ser/ 
AMCys)-(LyslArg/His)-Leu, which functions as a pero- 
xisome-targeting signal for many peroxisomal proteins 
[20-233, is absent in 3-oxoacyl-CoA thiolase [24-2G]. 
Swinkels et al. [27] have recently shown that the signal 
for directing peroxisomal3-oxoacyl-CoA thiolase to the 
peroxisomes resides in the N-terminal prcsequencc. It 
is conceivable that the primary defect in RCDP is a 
mutation in a gene encoding a protein required for the 
import into peroxrsomes of 3-oxoacyl-CoA thiolasc and 
a few other proteins. 
Another peroxisomal protein synthesised as a larger 
precursor with a cleavable N-terminal presequence is 
non-specific lipid transfer protein (nsLTP), also known 
as sterol carrier protein 2 [28,29]. In cells lacking func- 
tional peroxisomes, nsLTP is deficient [30-321 and the 
processing of the precursor of nsLTP is impaired [31]. 
in both these respects the behaviour of nsLTP resem- 
bles that of 3-oxoacyl-CoA thiolase. Since there is a 
striking homology in the amino acid sequence upstream 
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of the processing site in the two proteins (see [2,33]), a 
single peroxisomal protease ‘may be responsible for the 
processing of both proteins. Furthermore, these facts 
suggest that the protease is deficient in cells lacking 
peroxisomes. From cDNA analysis it is evident that 
nsLTP has been highly conserved between mammalian 
species and that, in contrast o peroxisomal 3-oxoacyl- 
CoA thiolase [34], it contains the C-terminal tripeptide 
sequence, -Ala-Lys-Leu, which could function as a pe- 
roxisomal targeting signal [33,35-371. It was therefore 
of interest o investigate whether or not nsLTP shows 
the same abnormalities ES peroxisomal 3- oxoacyl-CoA 
thiolase in fibroblasts from RCDP patients. This paper 
describes the results of the study, 
1234567 
2. MATERIALS AND METHODS 
Fig. I. Immunoblot analysis of fibroblasts from control subjects, aZS 
patient and RCDP patients using antibodies directed against rat-liver 
non-specific lipid transfer protein (nsLTP), For experimental dctuils 
set Materials and Methods. (1) Control Rbroblasts (100 yg); (2) ZS 
fibroblasts (cell line GRO87AD, 100 rg); (3) RCDP fibroblasts (cell 
line MCHESSAD. IOOyg); (4) control fibroblasts (1Obyg); (5) RCDP 
fibroblasts (cell line GJOLD90AD, 100 yg); (6) pre-nsLTP from rat 
2. I. Ceil lint3 ard clrlrwr comiirions 
Cuhured skin fibroblasts used in these studies were obtained from 
control subjects, from paiicnts with clinical and biochemical ma- 
nifestations characterislic of RDCP (cell lines MCHESSAD and 
GJOLD90AD; see [14] for dclails) and from a patient with ZS (cell 
line GR087AD; see [38] for details). The cells were cultured in a 
one-ro-one mixture of Ham FIO (Gibco, Glasgow, UK) and 
Dulbccco’s modified Eagle medium (Gibco) supplemented with IO% 
(by vol.) foelal calf serum (Gibco), under 5% CO:. 
liver; (7) lOO,r\f10 x g rar-liver supernatant. 
ment with earlier results obtained with liver homo- 
genates and fibroblasts from control subjects and ZS 
patients [30,31]. 
Fibroblasts were homogenidcd and fraciionated on linear Nycadenz 
gradients (10-408) exactly 21s described by Wanders et al. [39]. 
In RCDP fibroblasts the molecular weight of nsLTP 
was identical to that of the mature protein seen in con- 
trol fibroblasts, indicating that the processing of nsLTP 
is not impaired. Furthermore, the amount of cross-reac- 
tive material was comparable to that in control fi- 
broblasts. 
The activity of glutamate dehydrogenase, lactate drhydrogenasc, 
catalase and /5hcxosaminidas: war, measured as described previously 
1401. 
3.2. Subcrllular loca/isatio,z of the nsLTP 
Samples wcrc subjected to electrophoresis on IO-18% polyacryl- 
amide gmdicnt gels essentially as described by Laemmli [41]. Immu- 
noblot analysis was pcrformcd as described previously [14]. Nitrocel- 
lulose sheets were incubated overnight with affinity-purified antibod- 
ies directed against rat-liver nsLTP prepared as described by Teetlink 
et al. [42] or with antibodies directed against 3-oxoacyl-CoA thiolasc 
as described previously [14]. Antigen.-antibody complexes were 
visualised by incubation with goat anti-rabbit Ig conjugated to per- 
oxidase, tbllowcd by colour developmenl using tetramethylhenzidinc 
(Sigma, SL. Louis, MO, USA). 
To study the subcellular locaiisation of nsLTP in 
RCDP, cultured skin fibroblasts were fractionated on 
continuous Nycodenz gradients as described in Ma- 
terials and Methods. The results are shown in Fig. 2. As 
judged by the distribution of the activities of marker 
enzymes, the peroxisomes, mitochondria and cytosol 
were well resolved from each other in these gradients. 
The distribution of the marker enzymes was similar in 
gradients of RCDP fibroblasts and contrtil cells. 
nsLTP from rat liver was isolaled as described in [43]. Rat-liver 
prc-nsLTP was overexpressed in Exiwichfa co/i and purilied from the 
bacterial lysate as dexribed in [44]. 
3. RESULTS 
Immunoblot analysis revealed that nsLTP was pres- 
ent in peroxisomal fractions from RCDP fibroblasts 
and that the amount of antigen was comparable to that 
in the peroxisomal fractions of coniroi cells (Fig. 3). In 
contrast, peroxisomal 3-oxoacyl-CoA thiolase was not 
present in peroxisomal fractions from RCDP fi- 
broblasts (Fig. 3), as described previously [13,14,16]. 
3.1. Immrmoblot anuiysis of the nsLTP iH cultured skin 
fibrobiusts 4. DISCUSSION 
An immunoblotting experiment was carried out using Immunoblotting of cultured skin fibroblasts revealed 
antibodies directed against nsLTP. The results are that nsLTP, which is synthesized as a precursor protein 
shown in Fig. 1. In fibroblasts from control subjects the with an N-terminal peptide extension, is processed CO its 
cross-reactive immunologicai material present cor- mature r^orm in fibrobiasts irom RCDP patients, ~1s i
responded to the 14 kDa mature form of nsLTP. In ZS the case in cells from cor&\>l subjects, Subcellular 
fibroblasts the amount of cross-reactive material was fractionation studies revealed tnat the ;vJature form of 
below the limit of der.xtion. These findings are in agree- nsLTP was located i3 the peroxisomal fi,actions of both 
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Fig. 2. Subcellular fractionation of fibroblasts from a control subject 
and an RCDP patient on Nyr;odenz gradients. Fibroblast homo- 
genates from a control subject and an RCDP patient were prepared 
and fractionated as described in Materials and Methods. Fractions 
were collected starting from the bottom of the tube and analysed for 
the activity of the marker enzymes; (A) glutamate dehydrogcnasc 
(mitochondria): (B) lactate dehydrogenasc ( ytosol); (C) catalase 
(peroxisomes); and (D) &hexosaminidase (lysoromes). Activities are 
expressed as percentages of total activity across the gradient. 
control and RCDP fibroblasts. We therefore conclude 
that the post-translational import of nsLTP into pero- 
xisomcs is not impaired in RCDP fibroblasts, in con- 
trast to the import of 3-oxoacyl-CoA thiolase. This indi- 
cates that at least one component of the import 
machinery is not common to nsLTP and 3.oxoacyl- 
CoA thiolase. 
The carboxy-terminal SKL tripeptide sequence, 
-(Ser/AlaKys)-(Lys/Arg/His)-Len, which has been 
identified as a peroxisomal targeting signal by Sub- 
ramani and co-workers [23] and others [21,22]; is pres- 
ent in nsLTP [33,35-371, but not in 3-oxoacyl-CoA 
thiolase [24-261. In patients with RCDP the machinery 
used for the import of proteins which contain this 
targeting signal seems to be intact. Thus, nsLTP could 
be imported into the peroxisomes of RCDP patients by 
use at’ its C-terminal SKL tripeptide. However, it can 
not be excluded that in control cells nsLTP is imported 
into the peroxisomes by the machinery which is in- 
volved in the import of 3-oxoacyl-CoA thiolase. 
The fact that nsLTP is processed to a 14 kDa mature 
form indicates that the putative peroxisomal protease 
responsible for its processing is normally active in 
RCDP fibroblasts. Sequence comparison revealed a 
striking homology between the amino acid sequence 
upstream of the processing site of nsLTP and 3-0xoacyE 
CoA thiolase [2,33], suggesting that a single peroxi- 
somal protease is responsible for the peroxisomal 
processing of both proteins. If this is indeed the case, it 
can be excluded that a mutation in a gene encoding a 
peroxisomal protease is responsible for the deficiency in 
the import of 3-oxoacyl-CoA thiolase in RCDP 
patients. Most likely the RCDP phenotype is caused by 
a mutation in a gene which encodes a receptor or an- 
other component of the import machinery which is in- 
CONTROL RCCIP 
Fraction 1: ‘+6 12 1 
P 
10 8 6 4 4 6 8 10 12 14 16 18 
number -f-I-f-I-i--I-f+++++ 19 17 15 13 11 9 7 5 5 7 9 11 13 15 17 19 
nsLTP 
15 kDa 
,4 kDa _-- :. 
14 ftDa 
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Fig. 3. lmmunoblot analysis of non=specific l pid tra&er protein (nsLTP) and 3-oxoacyl&A thiolase in fractions obtained after Nycodenz 
fractionation of fibroblast homogenates. Cultured skin fibroblasts from an RCDP patient and from a control subject were fractionated as in Fig. 
2. Aliquots of t’ir’o fractions were pooled 2nd subjected to immunoblot analysis by use of affinitypurified antibodies directed against rat liver nsLTP 
or antibodies directed against 3-oxoacyl-CoA thiolase as described in Materials and Methods. The first 8 lanes are fractions from the Smdicnt of 
control fibroblcsts; fractions 6 + 7 are the paroxisomal peak fractions. The next 8 lanes arc fractions from ahe gradient of RCDP fibroblasts; fractions 
8 t 9 are the peroxisomal peak fractions. M, mature form of nsLTP from rat liver; P, pm:ursor form of nsLTP from rat liver; “a-specific protein 
bands. 
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valved in the import of a specific group of peroxisomal 
proteins, inchiding 3-oxoacyl-CoA thiolase. 
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